However, based on our current understanding of their physiological and pathophysiological roles, Cav1.3 LTCCs also appear as attractive drug targets for the therapy of various diseases, including treatment‐resistant hypertension, spasticity after spinal cord injury and neuroprotection in Parkinson's disease. The gene discussed is CACNA1D; the disease is hypertensive disorder.